TXG
$69.86-3.50%
as of close, Oct 16, 2026
☾ AH $69.86 -3.50%
10x Genomics Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.01%Russell 3000 0.006%US Stock Market 0.006%
TXG — 10x Genomics Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
20.040.060.080.0100.0120.0140.0160.0180.0200.0010.0M20.0M$69.86—20192021202320252026
2026-10-16
Price$69.86
MA20$63.12
MA50$39.25
Vol3.4M
Key stats#
Price data
- Price
- $69.86
- YTD price return
- +328.33%
- YTD total return
- +328.33%
- Next earnings
- Nov 5, 2026 · After close
- Market cap
- 9.1B
- Enterprise value
- 8.7B
- Shares outstanding
- 130.3M
- 52W low
- $11.81
- 52W high
- $102.81
- From 52W high
- -32.05%
- From 52W low
- +491.78%
- 52W range
- 64%
Volume
- Rel volume
- 0.90×
- 30D volume
- 3.8M
- 30D $ vol
- 295.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$2.5M
- Insider net 3M
- −$12.2M
- Insider net 1Y
- −$16.2M
Form 4 transactions by trade date, as filed; latest on file 2026-09-22.
Fundamentals
- Sales (ttm)
- 616.9M
- Sales/share
- $4.73
- EPS (ttm)
- -$0.59
- FCF (ttm)
- 121.4M
- FCF/share
- $0.93
- Book value/share
- $6.34
- Net margin
- -12.18%
- ROE
- -9.10%
- ROA
- -7.29%
- Current ratio
- 5.69
Growth (CAGR, ttm) · 10Y
- Sales
- -4.28%+2.77%+8.74%n/a
- FCF
- +113.62%n/an/an/a
- Shares
- +4.65%+3.74%+3.47%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- -8.53%-0.94%+5.10%n/a
- FCF/share
- +104.14%n/an/an/a
- Book value/share
- +2.02%-2.31%-2.36%n/a
- Price
- +464.97%+21.46%-14.42%n/a
- Total return
- +464.97%+21.46%-14.42%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -118.8×
- Fwd P/E
- 953.3×
- P/S (ttm)
- 14.8×
- P/B (mrq)
- 11.0×
- P/FCF (ttm)
- 75.0×
- EV/Sales (ttm)
- 14.1×
- FCF yield (ttm)
- 1.33%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 63rd
- P/B
- 64th
Bar = where today’s multiple sits in TXG’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-16#
1D
-3.50%
5D
-13.38%
1M
-3.88%
3M
+57.06%
YTD
+328.33%
1Y
+464.30%
5Y
-54.12%
Recent filings#
- Sep 3Insider sale · STUELPNAGEL JOHN R (Director) sold 40,000 Class A shares for $2.4M on 2 days since Aug 11
- Aug 24Insider sale · Saxonov Serge (Chief Executive Officer · Director) sold 18,545 Class A shares for $1.2M at $63.02
- Aug 24Insider sale · Taich Adam (Chief Financial Officer) sold 17,166 Class A shares for $1.1M at $63.02
- Aug 24Insider sale · Hindson Benjamin J. (See Remarks · Director) sold 13,818 Class A shares for $871K at $63.02
- Aug 6Earnings · Earnings release — EPS −$0.14 vs −$0.23 est. (+39.1%); revenue $151.0M (−13% y/y) 14.1%
Financial statements
Open full TXG financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +10.48% | +0.43% |
| JNJ | Johnson & Johnson | -4.38% | +0.90% |
| ABBV | AbbVie Inc. | +8.73% | +0.71% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +6.97% | -1.29% |
| MRK | Merck & Co. Inc. | +0.72% | +0.52% |
| NVS | Novartis AG | +8.59% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +6.41% | -0.93% |
| AMGN | Amgen Inc. | +14.92% | -0.35% |
